XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue and Deferred Revenue
 9 Months Ended
Sep. 30, 2021
Revenue Recognition and Deferred Revenue [Abstract]  
Revenue and Deferred Revenue REVENUE AND DEFERRED REVENUE
Product revenue consists of instruments, consumables and platform evaluation agreements. Related party revenue is comprised of both the sale of products and services performed.
As of September 30, 2021 and December 31, 2020, the Company recorded $0.1 million and $0.3 million of contract liabilities, consisting of deferred revenue. None of the revenue recorded in the nine months ended September 30, 2021 was included in contract liabilities as of December 31, 2020. All contract liabilities are expected to be recognized as revenue in the next twelve months.
Research Agreements
In February 2019 and March 2020, the Company entered into sponsored research agreements with a biotechnology company and a pharmaceutical company, respectively, under which the Company is required to execute certain research and development activities for total aggregate consideration payable of $0.9 million. During the three and nine months ended September 30, 2021 and 2020, the Company did not recognize any revenue with respect to these agreements.
National Institutes of Health Grant
In August 2019, the Company received a notice of a Small Business Innovation Research grant award from the National Institutes of Health, which will provide funding of approximately $1.1 million to the Company for its development of research applications. In June 2020, the Company received a notice that additional grant consideration of $0.9 million will be awarded. During the three months ended September 30, 2021 and 2020, the Company recognized grant revenue of approximately $10,000 and $0.1 million, respectively, with respect to the award. During the nine months ended September 30, 2021 and 2020, the Company recognized grant revenue of $0.2 million and $0.3 million, respectively, with respect to the award.